Top of the morning to you. A cloudy day here at the Pharmalot corporate campus, where we are hustling the short people off to assorted schoolhouses and readying our agenda. And yes, we are downing another cup of stimulation. How else to cope with a long to-do list? We trust you can relate. To help you along, here are some items of interest. Hope your day goes well and stay in touch...
Obama Deficit Plan Targets Drugmakers (Associated Press)
Express Scripts To Tell Congress Medco Deal Would Cut Rx Costs (Bloomberg News)
UN Assembly Backs Steps To Fight Chronic Diseases (Reuters)
Bristol-Myers May Be A Takeover Target: Analyst (Associated Press)
Sanofi CEO Says US Pharma Is Undervalued (Reuters)
Gilead Experimental HIV Med Outperforms Rival In Study (Bloomberg News)
Pfizer To Invest $200M In Irish Facility (RTE News)
German Rx Reimbursement Spending Growth Slows (Pharma Times)
Russian Ministry OKs 600 Sites For Clinical Trials (Outsourcing Pharma)
Merck Sees Progress With HIV Treatment (Dow Jones)
Giving Flu Vaccine To Tots Cuts ER Visits (Reuters)
Glaxo Adds 32 Jobs Thanks To Montana Grant (The Missoulian)
South African Pharma Strikes Deal With India's Natco (Business Standard)
Serbia Arrests Ex-Health Official Over Flu Vaccine Procurement (B92.net)
EDITOR'S NOTE: Please check this post for updates throughout the morning
2 Comments
There are less than five companies that have the cash to acquire BMS. Why straight cash? Because companies, like individuals are massively delevereraging and restructuring debt in anticipation of what IMO will likely be another deep and sustained recession within the next two years. In these cases the last thing companies want to have on their balance sheets is more debt.
US pharmaceutical companies are the latest lap dogs for Prime Minister Putin. Six hundred clinical trial sites seems high, but realize that under the new rules drug companies must conduct trials in Russia if they want to sell their drugs there. I'm absolutely certain that the entire accreditiation process by the Russian Ministry was completely above board, with not even a whiff of under the table payments by US Big Pharma in order to jack up the previous number from 114 to 600 in a period of only 90 days.